Clegg, Lindsay E.
AstraZeneca (United States)
2 papers on CoChatORCID 0000-0001-8558-9341
Most cited papers
- Verified
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 94
- Verified
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
van der Aart‐van der Beek, A. B., Clegg, L. E., Penland, R. C., Boulton, D. W., Sjöström, C. D., Mentz, R. J., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes, Obesity and Metabolism
Chronic Kidney Disease and DiabetesDiabetes Treatment and Management
Cited by 37
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free